Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

W. Eiermann(Ludwig-Maximilians-Universität München), Semiglazov Vf, L. Mauriac(Institut Bergonié), Antonio Llombart‐Cussac(Universidad Cardenal Herrera CEU), Justus Appfelstaedt(Stellenbosch University), M. Borgs(Novartis (Switzerland)), Stefan Paepke(Charité - Universitätsmedizin Berlin), Matthew J. Ellis(Washington University in St. Louis), M. Lassus(Novartis (Switzerland)), Hilary A. Chaudri‐Ross(Novartis (Switzerland)), J. Eremin(St George's Hospital), J. Vinholes(Santa Casa Hospital), Margaret Dugan
Annals of Oncology
November 1, 2001
10.1023/a:1013128213451
Cited by 714

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial
|Journal of Clinical Oncology|2001|1.1k